Search

The article discusses the development of a therapeutic protein called UbiquiNaV, which targets the NaV1.8 sodium channel to reduce sensory neuronal excitability and potentially alleviate chronic pain. The protein was shown to decrease channel expression in the plasma membrane, reduce NaV1.8 currents in rodent sensory neurons, and normalize neuronal hyperexcitability in models of inflammatory and chemotherapy-induced neuropathic pain. The research suggests that selective ubiquitination of NaV1.8 channels could be a promising strategy for developing non-addictive pain therapeutics. [Extracted from the article]

A study conducted by the Chinese Academy of Sciences in Beijing, People's Republic of China, focused on developing a dual-sensor platform for visualizing polyubiquitin chain assembly in live cells. The platform utilized macrocyclic peptides and a tetraphenylethylene derivative to enable fluorescent readout of polyubiquitin linkage type without disrupting the cellular environment. The research demonstrated the potential of these sensors in assessing the mechanism of action and potency of proteolysis-targeting chimeras (PROTACs) for drug development. This peer-reviewed study offers valuable insights into protein ubiquitination processes and drug discovery. [Extracted from the article]

A recent study conducted by investigators from Harbin Medical University in Heilongjiang, China, focused on a novel 167-amino acid protein encoded by circPCSK6 that inhibits the progression of intrahepatic cholangiocarcinoma (ICC) by targeting the NF-kappa B pathway. The research highlighted the importance of circPCSK6 and its derivative in ICC pathogenesis, emphasizing their potential as therapeutic targets. The study also identified EIF4A3 as a regulator of circPCSK6, impacting ICC malignancy, and suggested that higher levels of circPCSK6-167aa could enhance sensitivity to chemotherapy. This groundbreaking discovery offers new insights into circRNA-driven tumorigenesis and potential innovative therapeutic strategies for ICC treatment. [Extracted from the article]

The article discusses the heterogeneity of huntingtin inclusion bodies in Huntington's disease, highlighting the need for a better understanding of their role in the disease. The study used multiple antibodies to characterize the immunophenotypes of inclusion bodies and examined their ubiquitination profiles. Findings suggest that inclusion bodies with specific characteristics may be associated with disease severity and age of onset, emphasizing the importance of considering diversity in inclusion body composition for future research on Huntington's disease. [Extracted from the article]

A study highlighted in Women's Health Weekly discusses the role of the deubiquitinase USP7 in triple negative breast cancer (TNBC). The research reveals that USP7 is upregulated in TNBC patient tumors and its inhibition impairs tumor progression in TNBC models. The study suggests that USP7 plays a critical role in regulating proteins involved in cell proliferation, genome stability, and proteostasis in TNBC, making it a potential therapeutic target for this challenging disease subtype. [Extracted from the article]

Central South University researchers have published a study on the role of O-GlcNAcylation in endometrial cancer. The research found that O-GlcNAcylation levels are correlated with cancer grade and that manipulating these levels can impact cancer cell growth. The study suggests that O-GlcNAcylation could be a potential marker for stratifying and treating advanced endometrial cancer cases. [Extracted from the article]

Researchers from Cornell University have conducted a study on Wolbachia, a Gram-Negative Bacteria, and its impact on germline stem cells and gene expression in Drosophila. The study found that Wolbachia infection can rescue fertility defects in flies by interacting with genes related to ubiquitination and histone lysine methylation. This research sheds light on the mechanisms by which Wolbachia modulates germline stem cell gene function. The study was supported by the National Institutes of Health and Cornell University, and has been peer-reviewed. [Extracted from the article]

A patent has been issued for engineering the RRM2 subunit of ribonucleotide reductase to resist degradation by the University of Washington. The technology aims to increase ribonucleotide reductase activity and deoxynucleotide levels in cells, particularly cardiomyocytes, to enhance heart muscle performance. Mutant RRM2 proteins resistant to degradation through the ubiquitin-proteasome pathway have been developed, showing potential for treating cardiac diseases by stabilizing enzyme activity and increasing deoxynucleotide levels. [Extracted from the article]

Researchers from the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine have explored the role of ubiquitination modifications in migraine headaches. The study highlights the involvement of the ubiquitin-proteasome system in regulating MAPK and NF-kB signaling pathways, which play a crucial role in neuroinflammation and pain signal amplification associated with migraines. The research aims to provide insights into potential diagnostic, biomarker, and therapeutic response monitoring applications for migraine disease. [Extracted from the article]

A recent study published in Heart Disease Weekly highlights the role of the enzyme USP5 in breaking down unneeded or damaged proteins in the heart, crucial for heart health. Low levels of USP5 were found to lead to protein build-up in heart muscle cells, triggering dilated cardiomyopathy in animal models. Researchers suggest that targeting USP5 could potentially slow the progression of heart diseases caused by protein accumulation, but further research is needed to explore this potential therapeutic target. [Extracted from the article]

A patent application titled "ARRDC1-Mediated Microvesicles (ARMMS) Degrading System and Uses Thereof" was published online by inventors from Cambridge, MA, US. The application focuses on a system involving ARRDC1 fusion proteins for targeted protein degradation via the ubiquitin-proteasome pathway. The invention includes methods, nucleic acid constructs, microvesicles, and cells for degrading target proteins and altering gene expression. The patent application provides detailed information on the fusion proteins, targeting domains, and potential applications in protein degradation. [Extracted from the article]

A recent study from Sungkyunkwan University School of Medicine explores the role of the ubiquitin ligase Pellino1 in regulating inflammation and tumor development in colitis and colitis-associated colon cancer (CAC). The research suggests that Pellino1 targets STAT3 for ubiquitination, leading to pathogenic activation of STAT3 signaling in macrophages. These findings highlight a potential macrophage-specific ubiquitination signaling axis in the development of colitis and CAC, offering insights into potential treatments for chronic inflammation and inflammation-related cancer. [Extracted from the article]

Researchers at the University of Coruna have reported new findings on the Hakai protein, identifying it as an E3 ubiquitin ligase involved in the degradation of E-cadherin complex, leading to epithelial-to-mesenchymal transition. Recent research has also highlighted Hakai's noncanonical role in the N-6-methyladenosine writer complex, impacting RNA methylation and its potential as a cancer biomarker. The development of a small-molecule inhibitor targeting Hakai's atypical substrate binding domain shows promise for potential clinical applications. [Extracted from the article]

A study conducted at Second Xiangya Hospital in Changsha, People's Republic of China, explored the role of ubiquitin-specific peptidase 7 (USP7) in exacerbating acute pancreatitis (AP) progression by enhancing ATF4-mediated autophagy. The research found that USP7 knockdown reduced inflammation and cell injury during AP progression by inhibiting ATF4-mediated autophagy activation. This study sheds light on the regulatory mechanisms of autophagy in AP and highlights the potential therapeutic implications of targeting USP7 in managing AP. [Extracted from the article]

A study conducted at Harbin Medical University in the People's Republic of China explored the role of berberine in inhibiting inflammation associated with atherosclerosis. The research found that berberine reduced inflammation linked to senescence-associated secretory phenotypes (SASP) through the RXR alpha/PPAR gamma/NEDD4 signaling pathway. This study suggests that berberine may offer a novel approach to addressing SASP-associated inflammation in atherosclerosis. [Extracted from the article]

The article discusses the rise of antibiotic-resistant bacterial pathogens and the need for innovative therapeutic approaches. It explores the use of host-targeted therapies focusing on deubiquitinating enzymes (DUBs) to regulate host-pathogen interactions during bacterial infections. The study identifies UPS modulators that enhance bacterial clearance and highlights the potential of targeting the UPS as a host-directed antimicrobial strategy to combat antimicrobial resistance. [Extracted from the article]

Researchers at the Affiliated Hospital of Southwest Medical University have published a study on osteoporosis, a skeletal disorder characterized by reduced bone density and increased fracture risk, especially in the aging population. The study highlights the role of NEDD4 family E3 ligases in bone metabolism and osteoporotic pathology, suggesting potential therapeutic targets for novel interventions. This research offers insights into the mechanisms of osteoporosis and presents new avenues for targeted drug development in the field. [Extracted from the article]

A recent study from Southern Medical University in Guangzhou, China, focused on the potential of pristimerin, a natural compound, in treating triple-negative breast cancer (TNBC). The research found that pristimerin activates the Vav1/ERK pathway by promoting the ubiquitination and degradation of HSPA8, leading to cell autophagy and apoptosis. This study sheds light on a potential new approach to treating TNBC and was supported by the Natural Science Foundation of Guangdong Province. [Extracted from the article]

A study from Wenzhou Medical University explores the role of AdipoR1 in enhancing radiation resistance in liver cancer cells. The research suggests that AdipoR1 regulates radiation resistance through the 'AdipoR1/ESR1/CCNB1IP1/cyclin B1' axis, impacting cell cycle progression. The findings may lead to the development of targeted radiosensitizing drugs, offering potential advancements in liver cancer treatment. For more information, the full article is available in Molecular Medicine, with contact information for the researchers provided. [Extracted from the article]

A recent study from Xuzhou Medical University explores the role of a novel peptide encoded by circSRCAP in conferring resistance to enzalutamide in castration-resistant prostate cancer (CRPC). The research suggests that circSRCAP inhibits the ubiquitin-dependent degradation of AR-V7, a key factor in ENZ resistance. The study highlights circSRCAP as a potential therapeutic target for treating ENZ-resistant CRPC, offering insights into epigenetic mechanisms influencing AR-V7 stability. The findings provide valuable information for researchers and clinicians working in the field of prostate cancer treatment. [Extracted from the article]

Researchers from the Second Affiliated Hospital of Nanchang University in China have conducted a study on the role of ubiquitination in cancer lipid metabolism. The study highlights the importance of lipid metabolism in cancer development and the regulation of cancer lipid metabolism by intracellular proteins through ubiquitination modifications. The research aims to explore the potential therapeutic strategies based on these findings. For more information, the full article can be accessed in Frontiers in Oncology. [Extracted from the article]

A recent study conducted by researchers at the University of Castilla-La Mancha in Spain explored the interaction between the Zika virus NS5 protein and the cellular ubiquitin-like modifier-activating enzyme 1 (UBA1). The study found that UBA1 plays a proviral role in promoting viral replication in infected cells, and inhibiting UBA1 could potentially be a therapeutic target for Zika virus infections. The findings suggest that viruses like Zika have evolved to exploit cellular protein degradation pathways to aid in their infection cycles. The research was supported by various organizations and published in the Journal of General Virology. [Extracted from the article]

Researchers at New York University conducted a study on the KRAS splice variants, KRAS4A and KRAS4B, which play a role in membrane association. They identified BIRC6 as a ubiquitin ligase that interacts specifically with KRAS4A, leading to its ubiquitination and affecting its function. The study sheds light on the differential interactomes of the KRAS splice variants and the role of BIRC6 in modifying KRAS4A. This research was supported by various organizations including the National Institutes of Health and the Ramon Areces Foundation. [Extracted from the article]

Recent studies from Shaanxi Provincial People's Hospital in the People's Republic of China have identified Ubiquitin-conjugating enzyme E2T (UBE2T) as a key player in the development of chemoresistance in colorectal cancer. The research found that UBE2T levels were significantly elevated in chemoresistant colorectal cancer patients and cells, and its knockout rendered resistant cells sensitive to chemotherapy. The study concluded that UBE2T could be a potential target for overcoming chemoresistance in colorectal cancer treatment. [Extracted from the article]

The patent application by Gali PRAG focuses on bacterial systems for analyzing ubiquitylated polypeptides, which play a crucial role in cellular processes and are linked to various diseases like cancer, neurodegenerative diseases, and infectious diseases. The invention aims to provide methods for identifying agents that regulate ubiquitinating enzymes, determining enzyme capabilities, and identifying polypeptide substrates. The application also includes claims for compositions and kits related to the analysis of ubiquitylated polypeptides. This research contributes to a better understanding of the ubiquitin system and its implications in health and medicine. [Extracted from the article]

Researchers at Yokohama City University in Kanagawa, Japan, have discovered that the antipsychotic drug clozapine can be used as a new E3 ligand for PROTAC technology, which targets proteins for degradation. This finding has implications for drug discovery and the development of new therapies. The study showed that clozapine can induce the degradation of disease-related proteins, expanding the possibilities for molecular design of PROTACs. Financial support for this research was provided by various organizations, including AMED and the Japan Science & Technology Agency. [Extracted from the article]

Researchers at a Cancer Center in Guangdong, China, conducted a study on the role of the long noncoding RNA HOTAIR in osteogenesis and distraction osteogenesis (DO). They found that silencing HOTAIR promoted osteogenic differentiation in bone marrow-derived mesenchymal stem cells (BMSCs) and accelerated DO healing by mediating FTO ubiquitination. The study suggests that inhibitors of HOTAIR could be a promising strategy for patients undergoing DO treatment. The research was published in the Journal of Orthopaedic Translation and can be accessed for free online. [Extracted from the article]

Researchers at Hamad Bin Khalifa University have conducted a study on ubiquitination enzymes in cancer, focusing on their role in cancer cell biology and immune evasion. The study highlights the importance of the ubiquitin-proteasome system in essential life processes and its link to the development and spread of multiple cancers. The researchers also discuss potential therapeutic opportunities, including small-molecule inhibitors and PROTACs, for targeting the UPS pathway in human cancers. For more information, the full article is available in Cells journal. [Extracted from the article]

A study conducted at Ningxia University in China explored the potential anti-melanoma effects of Platycodin D (PD), a compound derived from Platycodon grandiflorum roots. The research found that PD inhibited melanoma tumor growth by targeting JAK2, which influenced macrophage polarization and mitochondrial function. These findings suggest that PD could be a promising candidate for cancer therapy by regulating tumor-associated macrophages. The study was funded by the National Natural Science Foundation of China and published in the Journal of Functional Foods. [Extracted from the article]

A patent application titled "Stat3 Degraders And Uses Thereof" was published online by inventors from Watertown, MA, US. The application focuses on the development of a compound, Compound A, for treating hematological and solid tumors by targeting the STAT3 protein. The application outlines methods for administering Compound A in liquid formulations or unit dosage forms to patients with hematological malignancies or solid tumors, such as lymphoma. The patent application emphasizes the importance of STAT3 signaling in tumor growth and immune suppression, suggesting that selective degradation of STAT3 could be an effective treatment for cancer. [Extracted from the article]

Researchers at Tsinghua University in Beijing, China, have developed a new strategy called FUSEP to study E2-specific Ubiquitin conjugation profiles in live cells with amino acid resolution. This method identified multiple E2 enzymes involved in non-lysine ubiquitination and revealed a novel post-translational modification, tyrosine ubiquitination, in human Cullin-1 protein. The study suggests that this toolbox could lead to the discovery of new E3 Ub ligases for potential therapeutic applications. The research was published in Nature Chemical Biology and was funded by various organizations in China. [Extracted from the article]

Researchers at the Institute of Chinese Materia Medica have published a study on periodontitis, a chronic inflammatory disease. They found that Eupalinolide B (EB), a natural product, can ameliorate periodontal inflammation and bone resorption by targeting the ubiquitin-conjugating enzyme UBE2D3. This research suggests that EB could be a potential therapeutic agent for treating periodontitis. The study was funded by the National Key Research And Development Program of China and the National Natural Science Foundation of China. [Extracted from the article]

A recent study conducted at Guang'anmen Hospital in Beijing, China, focused on screening Traditional Chinese Medicine compounds for inhibiting Uchl3 activity through molecular docking and deubiquitinating enzyme probe technology. The research aimed to develop small molecule inhibitors targeting Ubiquitin C-Terminal Hydrolase L3 (UCHL3) and found that Danshensu showed promising results in inhibiting UCHL3 activity. This study provides valuable insights for the development of therapeutic drugs targeting UCHL3 in the future. For more information, readers can refer to the Journal of Visualized Experiments for the full research article. [Extracted from the article]

Researchers from Tsinghua University in Beijing, China, have conducted a study on targeted protein degradation using molecular glues and proteolysis-targeting chimeras (PROTACs) to eliminate disease-causing proteins. They found that (S)-ACE-OH, a metabolite of the antipsychotic drug acepromazine, acts as a molecular glue to induce protein degradation. This research highlights the potential of TRIM21-based multimer-selective degraders in addressing diseases caused by aberrant protein assemblies such as autoimmunity, neurodegeneration, and cancer. The study has been peer-reviewed and published in Cell. [Extracted from the article]

The article discusses a clinical trial, NCT06766435, evaluating the Abbott i-STAT TBI Biomarker Test's impact on reducing CT utilization among adult emergency department patients with suspected traumatic brain injury. The test measures glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in whole blood to aid in determining the need for head CT imaging in adults with mild TBI. The trial aims to assess the real-world impact of the biomarker test on CT head utilization and understand how a negative TBI biomarker result influences clinicians' decisions regarding head CT scans. [Extracted from the article]

A recent study from Sun Yat-sen University explores the role of assembly and maturation factors (AMFs) in breast cancer, finding that they are upregulated in the disease and associated with poor patient outcomes. Specifically, the oncogenic activation of DCAF13, an AMF candidate, promotes uncontrolled proliferation in breast cancer cells by enhancing Pol I transcription through K63-linked ubiquitination of RPA194. This dysregulation of RPA194 modification contributes to cancer progression. The research sheds light on the mechanisms driving breast cancer development and potential therapeutic targets. [Extracted from the article]

A patent has been issued for IRAK4 degraders and their synthesis by Kymera Therapeutics Inc. The patent focuses on the Ubiquitin-Proteasome Pathway (UPP) and the role of IRAK4 in innate immunity. The invention provides a composition for treating autoimmune/autoinflammatory diseases and a method for synthesizing compound I-1. The patent details impurity compounds and their percentages in the composition. [Extracted from the article]

A recent study from the Indian Institute of Science explores the dysregulation of Frizzled receptors in Alzheimer's disease, focusing on their role in synapse loss. The research highlights the importance of the Wnt signaling pathway in synaptic assembly and reveals a decrease in Frizzled receptor 7 levels in synaptosomes of APP/PS1 mice, leading to increased phosphorylation and ubiquitination of b-catenin. These findings suggest that elevated Wnt signaling may contribute to synapse loss in Alzheimer's disease. The study provides valuable insights into the molecular mechanisms underlying synaptic dysfunction in AD. [Extracted from the article]

Recent research from the Pennington Biomedical Research Center in Baton Rouge, Louisiana, explores the role of the E3 Ubiquitin Ligase2 Siah2 in regulating age-associated lipid turnover in adipose tissue macrophages (ATMs). The study suggests that aging may downregulate Siah2 activity in ATMs, leading to dysfunctional lipid metabolism and potentially contributing to obesity-related insulin resistance. By using a macrophage-specific Siah2 knockout mouse model, researchers found that Siah2 functions as a critical lipid sensor in ATMs, affecting lipid uptake, lysosomal delivery of lipid droplets, and metabolic processes. This study sheds light on the complex mechanisms underlying obesity and inflammation in adipose tissue. [Extracted from the article]